Abstract
Arundic acid has been experimented in vitro and in vivo as a potential neuroprotective agent. It modulates astrocyte activation by inhibiting the enhanced astrocytic synthesis of S-100β protein, responsible for inducing neuronal death. The phase II clinical trials for the treatment of acute ischemic stroke, as well as clinical development in other neurodegenerative diseases including amytrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease are recently completed. There is no review published in this area since its discovery as potential neuroprotective agent and the various syntheses reported for this important non-natural compound. This review summarizes the studies towards the development of arundic acid as a neuroprotective agent, the biological studies in vitro and in vivo, the phase II trials and the various efforts made for its synthesis in the last two decades.
Keywords: Alzheimer‘s disease, astrocyte modulation, ischemic stroke, neuroprotection, Parkinson‘s disease, synthesis.
Current Medicinal Chemistry
Title:Arundic Acid a Potential Neuroprotective Agent: Biological Development and Syntheses
Volume: 20 Issue: 18
Author(s): Rodney A. Fernandes and Arun B. Ingle
Affiliation:
Keywords: Alzheimer‘s disease, astrocyte modulation, ischemic stroke, neuroprotection, Parkinson‘s disease, synthesis.
Abstract: Arundic acid has been experimented in vitro and in vivo as a potential neuroprotective agent. It modulates astrocyte activation by inhibiting the enhanced astrocytic synthesis of S-100β protein, responsible for inducing neuronal death. The phase II clinical trials for the treatment of acute ischemic stroke, as well as clinical development in other neurodegenerative diseases including amytrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease are recently completed. There is no review published in this area since its discovery as potential neuroprotective agent and the various syntheses reported for this important non-natural compound. This review summarizes the studies towards the development of arundic acid as a neuroprotective agent, the biological studies in vitro and in vivo, the phase II trials and the various efforts made for its synthesis in the last two decades.
Export Options
About this article
Cite this article as:
Fernandes Rodney A. and Ingle Arun B., Arundic Acid a Potential Neuroprotective Agent: Biological Development and Syntheses, Current Medicinal Chemistry 2013; 20 (18) . https://dx.doi.org/10.2174/0929867311320180003
DOI https://dx.doi.org/10.2174/0929867311320180003 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Emerging Targets for Stimulant Use Disorders: Where To Invest In An Era Of Constrained Resources?)
CNS & Neurological Disorders - Drug Targets Clinical Applications for Cardiovascular Magnetic Resonance Imaging at 3 Tesla
Current Cardiology Reviews P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued) Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain
Current Neuropharmacology Glucocorticoids in Pregnancy
Current Pharmaceutical Biotechnology The Impact of Opioids on Cardiac Electrophysiology
Current Cardiology Reviews Type 1 Diabetes Treatments Based on Stem Cells
Current Diabetes Reviews MiR-34a Inhibits Spinal Cord Injury and Blocks Spinal Cord Neuron Apoptosis by Activating Phatidylinositol 3-kinase (PI3K)/AKT Pathway Through Targeting CD47
Current Neurovascular Research Imidazoles as Potential Antifungal Agents: A Review
Mini-Reviews in Medicinal Chemistry The Therapeutic Role of Lamotrigine and Topiramate in A Depressive Patient with Anxiety Symptoms and Cognitive Decline: Neurometabolic Correlates
Current Clinical Pharmacology Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets 8-(Trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine: Novel Aminobenzopentathiepine having In Vivo Anticonvulsant and Anxiolytic Activities
Letters in Drug Design & Discovery Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry Bacterial Recognition and Induced Cell Activation in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Modern Spectrum of Rhabdomyolysis: Drug Toxicity Revealed by Creatine Kinase Screening
Current Drug Safety The Experience of Combining Agents, Specially Triptans and Non Steroidal Anti-Inflammatory Drugs, for the Acute Treatment of Migraine - A Review
Recent Patents on CNS Drug Discovery (Discontinued) Impact of New Technologies on Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics
Current Pediatric Reviews Meet Our Editorial Board Member
Current Neuropharmacology